AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ACDC Metals Ltd

0.043

+0.000

Volume:- -

Turnover:- -

Market Cap:3.15M

PE:-7.67

High:0.043

Open:0.043

Low:0.043

Close:0.043

Loading ...

Overview Company News Filings

Lotte Biologics Signs ADC Production Deal, Launches Full-Scale Operations at Syracuse Facility

MT Newswires Live

Agree Realty Prices Public Share Offering at $75.70 a Share

MT Newswires Live

Shandong Boan Biotechnology Cancer Drug Granted U.S. FDA Orphan Drug Designation

MT Newswires Live

Otsuka's Taiho to Buy Swiss ADC Developer Araris Biotech

MT Newswires Live

CStone Pharmaceuticals Submit Clinical Trial Application in Australia for Cancer Drug

MT Newswires Live

Sichuan Biokin Pharmaceutical Enrolls First Patient for Lung Cancer Trial; Shares Down 4%

MT Newswires Live

Coles share price lifts off on dividend boost

Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod for Solid Tumors Drug

MT Newswires Live

Market Chatter: Samsung Biologics Ventures in Antibody-Drug Conjugate Market with New Facility

MT Newswires Live

Samsung Biologics Expands ADC Collaboration with LigaChem Biosciences

MT Newswires Live

Agree Realty Expects to Invest Up to $1.3 Billion in 2025

MT Newswires Live

Innovent Bio Grants Roche Exclusive Global Rights to ADC Targeting DLL3

MT Newswires Live

Is the Coles share price a buy amid its 2025 outlook?

Trump Media saw the largest increase in short interest in October

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ADC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","market":"AU","secType":"STK","nameCN":"ACDC Metals Ltd","latestPrice":0.043,"timestamp":1746598320000,"preClose":0.043,"halted":0,"volume":0,"delay":0,"nameEN":"ACDC Metals Ltd","floatShares":39337511,"shares":73275130,"eps":-0.005605,"marketStatus":"Not Yet Opened","change":0,"latestTime":"05-07 16:12:00 AEST","open":0.043,"high":0.043,"low":0.043,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.005605,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746662400000},"marketStatusCode":0,"adr":0,"listingDate":1673787600000,"exchange":"ASX","adjPreClose":0.043,"openAndCloseTimeList":[[1746576000000,1746597600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","floatShares":39337511,"roa":"-3.02%","roe":"-3.81%","lyrEps":-0.006941,"shares":73275130,"dividePrice":0,"high":0.043,"amplitude":0,"preClose":0.043,"low":0.043,"week52Low":0.041,"pbRate":"0.30","psRate":"-130.70","week52High":0.095,"institutionHeld":0,"latestPrice":0.043,"eps":-0.005605,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.005605,"open":0.043,"prevYearClose":0.055,"prevWeekClose":0.043,"prevMonthClose":0.043,"prevQuarterClose":0.045,"fiveDayClose":0.043,"twentyDayClose":0.045,"sixtyDayClose":0.052},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530970964","title":"Lotte Biologics Signs ADC Production Deal, Launches Full-Scale Operations at Syracuse Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2530970964","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530970964?lang=en_us&edition=fundamental","pubTime":"2025-04-25 16:52","pubTimestamp":1745571122,"startTime":"0","endTime":"0","summary":"Lotte  subsidiary Lotte Biologics signed a contract with an unnamed Asian biotech firm to manufacture clinical trial materials for an antibody-drug conjugate , marking the launch of its $100 million ADC production facility at the Syracuse Bio Campus in New York.The cGMP-compliant plant offers integrated one-stop contract development and manufacturing organization services, from development to commercial-scale manufacturing, Lotte Biologics said Thursday.Shares of Lotte rose nearly 1% at market close on Friday, April 25.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4080","BK4231","ADC","ADC.AU","BK7095"],"gpt_icon":0},{"id":"2529676809","title":"Agree Realty Prices Public Share Offering at $75.70 a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2529676809","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529676809?lang=en_us&edition=fundamental","pubTime":"2025-04-24 17:02","pubTimestamp":1745485364,"startTime":"0","endTime":"0","summary":"Agree Realty  said Wednesday it priced a public offering of 4.5 million common shares at $75.70 per share in connection with its forward sale agreement with Bank of America as the forward purchaser.Under the forward sale agreement, the forward purchaser or its affiliates are expected to borrow and sell to the underwriter the 4.5 million shares that will be issued through the public offering.The company said it also granted the underwriter a 30-day option to purchase up to 675,000 additional common shares.Agree Realty expects to close the offering around Friday and said it will not initially receive any proceeds from the sale by the forward purchaser.Proceeds from the future settlement of the forward sale deal will be used for general corporate purposes, the company added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0098860793.USD","LU1880398471.USD","IE00BBT3K403.USD","LU1366192091.USD","LU2133065610.SGD","LU0310800965.SGD","BK4588","LU1162221912.USD","LU0306806265.USD","BK4581","LU1267930227.SGD","LU0256863811.USD","LU1894683264.USD","IE00B19Z3B42.SGD","LU0128525689.USD","LU2129689514.USD","IE00BFXG1179.USD","LU0683600562.USD","LU0477156797.USD","LU0130102774.USD","BK7095","LU0208291251.USD","BK4585","IE00BLSP4239.USD","BK4207","LU0971096721.USD","LU0149725797.USD","LU1496350502.SGD","ADC","LU0980610538.SGD","BK4534","LU1280957306.USD","IE00BKVL7J92.USD","LU0321505439.SGD","LU1506573853.SGD","LU1668664300.SGD","IE00B7SZLL34.SGD","LU0320765646.SGD","LU2129689431.USD","LU0130103400.USD","LU0417517546.SGD","BK4559","LU1201861165.SGD","LU0130518102.USD","LU0314106906.USD","ADC.AU","LU0320765489.SGD","LU0053666078.USD","LU1074936037.SGD"],"gpt_icon":1},{"id":"2522134338","title":"Shandong Boan Biotechnology Cancer Drug Granted U.S. FDA Orphan Drug Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2522134338","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522134338?lang=en_us&edition=fundamental","pubTime":"2025-03-27 15:44","pubTimestamp":1743061459,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology  said its novel CD228-directed antibody-drug conjugate , BA1302, received Orphan Drug Designation  from the Food and Drug Administration  for the treatment of squamous non-small cell lung cancer  and pancreatic cancer, according to a Wednesday filing with the Hong Kong bourse.BA1302 targets CD228, a protein overexpressed in multiple tumors, to inhibit cancer cell migration and proliferation while minimizing off-target toxicity.The biopharmaceutical company's shares were up 2% in recent trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4080","BK4183","ADC","BK4231","06955","BK7095","ODD","ADC.AU","BK1161"],"gpt_icon":0},{"id":"2520635265","title":"Otsuka's Taiho to Buy Swiss ADC Developer Araris Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2520635265","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520635265?lang=en_us&edition=fundamental","pubTime":"2025-03-18 08:06","pubTimestamp":1742256371,"startTime":"0","endTime":"0","summary":"Otsuka Holdings  said its unit, Taiho Pharmaceutical, will acquire Swiss biotech firm Araris Biotech for up to $1.14 billion to strengthen its antibody-drug conjugate  pipeline, according to a Monday filing on the Tokyo Stock Exchange.Taiho will pay $400 million upfront and potential additional milestone payments of up to $740 million. The deal is expected to close in the first half of 2025.Price : $7712.00, Change: $+94, Percent Change: +1.23%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4080","BK4231","ADC","ADC.AU","BK7095"],"gpt_icon":0},{"id":"2517185242","title":"CStone Pharmaceuticals Submit Clinical Trial Application in Australia for Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2517185242","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517185242?lang=en_us&edition=fundamental","pubTime":"2025-03-06 14:46","pubTimestamp":1741243589,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  submitted the Phase I-B trial application in Australia for its large B-cell lymphoma  drug, according to a Thursday filing with the Hong Kong bourse.CS5001 is an ROR1-targeting antibody-drug conjugate  that works with first-line standard-of-care  to diffuse large B-cell lymphoma , the filing added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4080","02616","ADC","XKO.AU","BK4231","XAO.AU","XJO.AU","BK7095","ADC.AU","BK1161","BK1574"],"gpt_icon":0},{"id":"2516576704","title":"Sichuan Biokin Pharmaceutical Enrolls First Patient for Lung Cancer Trial; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516576704","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516576704?lang=en_us&edition=fundamental","pubTime":"2025-03-03 12:21","pubTimestamp":1740975711,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical  said the first patient was enrolled in its phase three trial for BL-B01D1, according to a Monday filing with the Shanghai bourse.BL-B01D1 is a dual antibody-drug conjugate  combined with Osimertinib for treating EGFR-mutated advanced non-small cell lung cancer.Shares of the pharmaceutical company were down 4% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688506","BK7095","BK4080","ADC.AU","ADC","BK0239","BK4231"],"gpt_icon":0},{"id":"2514789050","title":"Coles share price lifts off on dividend boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2514789050","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514789050?lang=en_us&edition=fundamental","pubTime":"2025-02-27 07:33","pubTimestamp":1740612790,"startTime":"0","endTime":"0","summary":"Commenting on the results boosting the Coles share price today, CEO Leah Weckert said:  We have had a strong focus on value, fresh quality and availability which has supported volume-led growth in Supermarkets during the half…Looking at what could impact the Coles share price in the months ahead, the company reported that in the first seven weeks of the third quarter , its Supermarkets sales revenue grew by 3.4% compared to the same period last year. Coles Liquor segment posted sales revenue growth of 3.8%. \"Our focus in the second half remains on providing a compelling customer value proposition, making further progress on improving our fresh offer and continuing to tailor our ranges to make","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/27/coles-share-price-lifts-off-on-dividend-boost/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7040","BK4080","ADC.AU","XJO.AU","BK4231","BK7082","ADC","COL.AU","BK7095","BK7501"],"gpt_icon":0},{"id":"2505627362","title":"Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod for Solid Tumors Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2505627362","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505627362?lang=en_us&edition=fundamental","pubTime":"2025-01-21 10:39","pubTimestamp":1737427147,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  said they received a clinical trial approval for SKB445 from the Center for Drug Evaluation of the National Medical Products Administration on Jan. 20, according to a Monday filing with the Hong Kong Stock Exchange.SKB445, a new antibody-drug conjugate  drug, shows promise in treating advanced solid tumors, demonstrating efficacy and safety in preclinical studies using OptiDCTM technology, the filing added.The pharmaceutical company's shares were up by 1% in recent trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","LU0196878994.USD","ADC.AU","BK4080","06990","BK4231","ADC","BK1161"],"gpt_icon":0},{"id":"2504972351","title":"Market Chatter: Samsung Biologics Ventures in Antibody-Drug Conjugate Market with New Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2504972351","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504972351?lang=en_us&edition=fundamental","pubTime":"2025-01-17 10:18","pubTimestamp":1737080302,"startTime":"0","endTime":"0","summary":"Samsung Biologics  entered the antibody-drug conjugate  sector, with its new 500-liter ADC production facility in Songdo, Incheon, set to commence operations in February, The Korea Herald reported Thursday.ADCs combine monoclonal antibodies targeting cancer cells with potent drugs to improve therapeutic precision and efficacy, the report said.The Songdo facility is a four-story unit that features large-scale purification capabilities and streamlined quality control systems, it said.The company has deepened its collaboration with LigaChem Biosciences , signing a material transfer agreement in June 2024 and committing to more than three ADC projects in 2025, the report said.Shares of Samsung Biologics fell more than 1% in recent trade on Friday while those of LigaChem Biosciences fell nearly 1%.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4080","ADC.AU","BK7095","ADC","BK4231"],"gpt_icon":0},{"id":"2502072716","title":"Samsung Biologics Expands ADC Collaboration with LigaChem Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2502072716","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502072716?lang=en_us&edition=fundamental","pubTime":"2025-01-10 08:57","pubTimestamp":1736470660,"startTime":"0","endTime":"0","summary":"Samsung Biologics  extended its partnership with LigaChem Biosciences to provide antibody-drug conjugate  services at its new ADC facility, the South Korean biotechnology firm said Thursday.The collaboration focuses on ADC programs for solid tumor treatments. Samsung's facility, equipped with a 500-liter reactor, offers end-to-end ADC services from development to conjugation, using its expertise in large-scale antibody manufacturing, it said.Shares of Samsung Biologics rose nearly 1% in recent trade on Friday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","BK4080","BK4231","ADC.AU","ADC"],"gpt_icon":0},{"id":"2501601762","title":"Agree Realty Expects to Invest Up to $1.3 Billion in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501601762","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501601762?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:32","pubTimestamp":1736199169,"startTime":"0","endTime":"0","summary":"Agree Realty  said Monday it expects to invest $1.1 billion to $1.3 billion in 2025.The investments will include capital deployment through the acquisition, development and developer funding platform, the company said.Total real estate investment volume in 2024 was $951 million, the company said.Share of Agree Realty fell 1.8% in recent after-hours activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC","BK4231","ADC.AU","BK7095","BK4080"],"gpt_icon":0},{"id":"2500999346","title":"Innovent Bio Grants Roche Exclusive Global Rights to ADC Targeting DLL3","url":"https://stock-news.laohu8.com/highlight/detail?id=2500999346","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500999346?lang=en_us&edition=fundamental","pubTime":"2025-01-02 13:10","pubTimestamp":1735794641,"startTime":"0","endTime":"0","summary":"Innovent Biologics (HKG:1801) granted Roche exclusive global rights to develop, manufacture, and sell IBI3009, a DLL3-targeted antibody-drug conjugate (ADC) candidate.This collaboration aims to bring ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2488822045.USD","ADC.AU","BK4231","LU2328871848.SGD","BK1583","01801","BK4080","BK1161","LU1969619763.USD","BK1589","ADC","BK7095"],"gpt_icon":0},{"id":"2491368303","title":"Is the Coles share price a buy amid its 2025 outlook?","url":"https://stock-news.laohu8.com/highlight/detail?id=2491368303","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491368303?lang=en_us&edition=fundamental","pubTime":"2024-12-13 06:11","pubTimestamp":1734041485,"startTime":"0","endTime":"0","summary":"The Coles Group Ltd  share price has gone through plenty of volatility this year, but it seems to be ending the year on a high, as shown on the chart below. With the company close to its 52-week high, we're going to look at whether the company is an attractive investment with 2025 in mind.  As one of the largest supermarket businesses in Australia, it's benefited from the inflationary period over the last couple of years. However, now that food inflation has significantly reduced, the sector is no longer getting an extra revenue boost. So, will Coles be able to keep growing?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/13/is-the-coles-share-price-a-buy-amid-its-2025-outlook/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["ADC.AU","BK7501","BK7095","WOW.AU","BK7082","BK7040","COL.AU","BK7511","EBIT","ADC","BK4231","BK4080"],"gpt_icon":0},{"id":"2485114959","title":"Trump Media saw the largest increase in short interest in October","url":"https://stock-news.laohu8.com/highlight/detail?id=2485114959","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485114959?lang=en_us&edition=fundamental","pubTime":"2024-11-20 23:57","pubTimestamp":1732118245,"startTime":"0","endTime":"0","summary":"hyejin kang/iStock via Getty Images Trump Media & Technology (DJT) and Lucid Group (LCID) saw the largest increases in short interest in October, while Expand Energy Corp. (EXE), and Pilgrim’s Pride (","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1141852985/image_1141852985.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1141852985/image_1141852985.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4312369-trump-media-saw-the-largest-increase-in-short-interest-in-october","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["HUM","AMTM","VRNS","HUM.AU","EAT","CNX","FOUR","LINE","SFM.AU","MDGL","OLLI","IWV","CRC","AMKR","SFM","GAP.AU","CART","MC","EXE","APO","GAP","ADC.AU","SWKS","BIRK","CELH","DJT","ENSG","ENPH","SIRI","DOCU","WEX","XLU","AAL","RBC","XLP","ODFL","VERX","NTRA","CORT","WHR","CG","PPC","AAL.AU","SMMT","LCID","ADC","PPC.AU"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC.AU\",market:\"AU\",,,undefined,":[]}}